Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology
Emi Kawakita, Daisuke Koya, Keizo Kanasaki
Cancers (2021) Vol. 13, Iss. 9, pp. 2191-2191
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

DPP4, a potential tumor biomarker, and tumor therapeutic target: review
Lu Sun, Yuhui Ma, Chenchen Geng, et al.
Molecular Biology Reports (2025) Vol. 52, Iss. 1
Closed Access | Times Cited: 1
Dipeptidyl peptidase 4 inhibitor reduces tumor-associated macrophages and enhances anti-PD-L1-mediated tumor suppression in non-small cell lung cancer
Bei Zuo, Tao Li, Xiaoyun Liu, et al.
Clinical & Translational Oncology (2023) Vol. 25, Iss. 11, pp. 3188-3202
Open Access | Times Cited: 14
Ugonin P inhibits lung cancer motility by suppressing DPP-4 expression via promoting the synthesis of miR-130b-5p
Chih‐Ying Wu, Shubham Suresh Ghule, Chih‐Chuang Liaw, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115483-115483
Open Access | Times Cited: 11
The impacts of dipeptidyl- peptidase 4 (DPP-4) inhibitors on common female malignancies: A systematic review
Anoosha Niazmand, Reza Nedaeinia, Nasimeh Vatandoost, et al.
Gene (2024) Vol. 927, pp. 148659-148659
Open Access | Times Cited: 4
Repurposing metabolic regulators: antidiabetic drugs as anticancer agents
Yogita Dhas, Nupur Biswas, M R Divyalakshmi, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 4
Τhiazolidine-4-One Derivatives with Variable Modes of Inhibitory Action Against DPP4, a Drug Target with Multiple Activities and Established Role in Diabetes Mellitus Type II
Dionysia Amanatidou, Phaedra Eleftheriou, Anthi Petrou, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 1, pp. 52-52
Open Access
Incretins and SGLT-2 inhibitors in diabetic patients with neuroendocrine tumors: current updates and future directions
Rosaria Maddalena Ruggeri, Erika Grossrubatscher, Eleonora Ciocca, et al.
Reviews in Endocrine and Metabolic Disorders (2025)
Open Access
Increased Risk of Cancer—An Integral Component of the Cardio–Renal–Metabolic Disease Cluster and Its Management
Eberhard Standl, Oliver Schnell
Cells (2025) Vol. 14, Iss. 8, pp. 564-564
Open Access
Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance
Ashwani Sharma, Tarun Virmani, A. Sharma, et al.
Diabetes Metabolic Syndrome and Obesity (2022) Vol. Volume 15, pp. 1845-1864
Open Access | Times Cited: 18
Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?
Emile Verhulst, Delphine Garnier, Ingrid De Meester, et al.
Cancers (2022) Vol. 14, Iss. 3, pp. 624-624
Open Access | Times Cited: 16
Sodium-Glucose Co-Transporter 2 Inhibitors May Change the Development of Urinary Tract and Hematological Malignancies as Compared With Dipeptidyl Peptidase-4 Inhibitors: Data of the Post-Hoc Analysis of a Nationwide Study
György Rokszin, Zoltán Kiss, Gábor Sütő, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 17
The Role of Post-Translational Modifications of Chemokines by CD26 in Cancer
Alexandra De Zutter, Jo Van Damme, Sofie Struyf
Cancers (2021) Vol. 13, Iss. 17, pp. 4247-4247
Open Access | Times Cited: 16
Sitagliptin attenuates Porphyromonas gingivalis virulence and inflammatory response in macrophage on titanium
Weilong Tang, Minquan Du, Shuang Zhang, et al.
Archives of Oral Biology (2023) Vol. 149, pp. 105659-105659
Open Access | Times Cited: 6
Cancer biology in diabetes update: Focusing on antidiabetic drugs
Emi Kawakita, Keizo Kanasaki
Journal of Diabetes Investigation (2024) Vol. 15, Iss. 5, pp. 525-540
Open Access | Times Cited: 2
Crosstalk between incretin hormones, Th17 and Treg cells in inflammatory diseases
Eloísa Martins da Silva, Victor Yuji Yariwake, Renan Willian Alves, et al.
Peptides (2022) Vol. 155, pp. 170834-170834
Closed Access | Times Cited: 8
In Silico Analysis of Individual Fractions of Bovine Casein as Precursors of Bioactive Peptides—Influence of Post-Translational Modifications
Piotr Mińkiewicz, Małgorzata Darewicz, Anna Iwaniak
Applied Sciences (2023) Vol. 13, Iss. 14, pp. 8091-8091
Open Access | Times Cited: 4
Incretin based therapy and pancreatic cancer: Realising the reality
Varun Suryadevara, Ayan Roy, Jayaprakash Sahoo, et al.
World Journal of Gastroenterology (2022) Vol. 28, Iss. 25, pp. 2881-2889
Open Access | Times Cited: 7
Soluble dipeptidyl peptidase-4 induces epithelial–mesenchymal transition through tumor growth factor-β receptor
Cheng-Wei Huang, Shih-Yi Lee, Chen-Xuan Du, et al.
Pharmacological Reports (2023) Vol. 75, Iss. 4, pp. 1005-1016
Closed Access | Times Cited: 3
Virtual screening strategy for anti-DPP-IV natural flavonoid derivatives based on machine learning
Gen Lu, Fei Pan, Xiaotong Li, et al.
Journal of Biomolecular Structure and Dynamics (2023) Vol. 42, Iss. 13, pp. 6645-6659
Closed Access | Times Cited: 3
Inhibition of Dipeptidyl Peptidase-4 Activates Autophagy to Promote Survival of Breast Cancer Cells via the mTOR/HIF-1α Pathway
Emi Kawakita, Fan Yang, Sen Shi, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4529-4529
Open Access | Times Cited: 3
The many facets of CD26/dipeptidyl peptidase 4 and its inhibitors in disorders of the CNS – a critical overview
Hans‐Gert Bernstein, Gerburg Keilhoff, Henrik Dobrowolny, et al.
Reviews in the Neurosciences (2022) Vol. 34, Iss. 1, pp. 1-24
Closed Access | Times Cited: 5
CD26 and Cancer
Oscar J. Cordero
Cancers (2022) Vol. 14, Iss. 21, pp. 5194-5194
Open Access | Times Cited: 5
Dipeptidyl Peptidase (DPP)-4 Inhibitor Impairs the Outcomes of Patients with Type 2 Diabetes Mellitus After Curative Resection for Colorectal Cancer
Akira Saito, Joji Kitayama, Hisanaga Horie, et al.
Cancer Research Communications (2021) Vol. 1, Iss. 2, pp. 106-114
Open Access | Times Cited: 7
Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth
Yuki Tanaka, Chikayo Iwaya, Takako Kawanami, et al.
Diabetology International (2021) Vol. 13, Iss. 3, pp. 480-492
Open Access | Times Cited: 6
Sitagliptin Potentiates the Anti-Neoplastic Activity of Doxorubicin in Experimentally-Induced Mammary Adenocarcinoma in Mice: Implication of Oxidative Stress, Inflammation, Angiogenesis, and Apoptosis
Mohamed M. Salama, Randa A. Zaghloul, Rania M. Khalil, et al.
Scientia Pharmaceutica (2022) Vol. 90, Iss. 3, pp. 42-42
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top